Form D · Biotechnology

GRADALIS, INC.

Carrollton, TX · CIK 0001457915

Offering snapshot reported Jun 12, 2025 · SEC filing

Reported sold
$12.7M
Offering amount: $30M
Investors reported
24
Form D · investor count
Minimum accepted
$250K
Reported outside-investor minimum
First sale
Jun 5, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 12, 2025Initial$12,725,000No comparison24SEC filing
Apr 2, 2018Initial$43,936,167No comparison36SEC filing
Feb 26, 2009PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Debt, Option to acquire, Other
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-548754
Common Stock

Source: Form D, filed Jun 12, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Joseph F. Berry Director
Ernest Bognar Executive
Joe C. Cunningham Director
Joe Cunningham, M.D. Director
Mark Early Executive
Harry R. Jacobson Director
Harry Jacobson, M.D. Director
Robert P. Landin Director
Renee Larson Executive
Thomas Lyles Director
John Nemunaitis Director, Executive
John Nemunaitis, M.D. Director, Executive
Scott Seaman Director
David M. Shanahan Director, Executive
Gladice Wallraven Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
2545 Golden Bear Drive Suite 110
Carrollton, TX, 75006